Myeloma Treatment Trial Showed High Response Rates
Researchers reported promising results from a phase 1b/2 study combining two potent therapies for multiple myeloma.
Updated on Sept. 23, 2026 in Cancer
Live Poll
Do you believe new medical drug combinations generally offer better outcomes for patients?
The MELT-MM clinical trial achieved a 100 percent objective response rate in patients with relapsed or refractory multiple myeloma. Participants received a combination of the drug mezigdomide and the antibody elranatamab, reaching a 92.3 percent stringent complete response rate.
Why it matters
The study suggests that adding mezigdomide can restore the effectiveness of elranatamab in patients with high tumor burdens. By reversing T-cell exhaustion, this therapeutic combination aims to improve T-cell fitness and patient outcomes in difficult-to-treat cancer cases.
The trial reported a 90.9 percent minimal residual disease-negative complete response rate across 13 evaluable patients. Side effects included neutropenia and fatigue, both occurring in 84.6 percent of the treatment group.
The players
International Myeloma Society
This global organization focuses on advancing research, education, and clinical care for patients diagnosed with multiple myeloma.
Seoul National University Hospital
This leading medical institution provides advanced clinical research and patient care services in South Korea.
The details
Patients were treated with a combination of the CELMoD mezigdomide and the BCMA x CD3 bispecific antibody elranatamab. The study split participants into two dosing cohorts to test the ability of mezigdomide to restore elranatamab cytotoxicity in high-burden settings.
Timeline
Between December 2024 and October 2025, investigators enrolled 15 trial patients.
The trial results were presented in 2026 at the International Myeloma Society Annual Meeting.
The Big Picture
The findings from the MELT-MM clinical trial mark a significant shift in addressing T-cell exhaustion in blood cancers. By demonstrating that combination therapies can restore cytotoxicity in high-tumor-burden environments, this research advances the broader field of bispecific antibody applications.
The high response rates provide potential new options for patients with relapsed or refractory multiple myeloma who have exhausted standard therapies. Patients should consult their oncologists regarding the current availability of clinical trials and the potential management of side effects like neutropenia.
The takeaway
This study highlights the potential for combination therapies to overcome drug resistance in advanced cancer care. Patients and their families are encouraged to monitor ongoing clinical trial enrollment to access emerging treatments for complex conditions.
What happens next
Part 2 of the MELT-MM trial is currently enrolling patients in Singapore and Korea to further compare the 0.3-mg and 0.6-mg mezigdomide dosing regimens.
Further reading
For more information on current treatment breakthroughs, visit the Cancer section.
More information
View the full details of the MELT-MM clinical trial record on the official government portal.
Source note: This article includes information reported by OncLive.
Live Poll
Do you believe new medical drug combinations generally offer better outcomes for patients?
